Evolus Q3 2026 Results: Net Loss of $12.5M, Loss Narrows
Evolus, Inc. is an aesthetic neurotoxin company that has incurred significant losses since inception and relies heavily on its licensing agreements with Daewoong and Symatese. The company is currently focused on the commercial success of Jeuveau and the regulatory approval process for its Evolysse product line.
- Key figure
- Net loss $12.5M